secwatch.observer — SEC 8-K summary
======================================

Issuer:     Schrodinger, Inc. (SDGR)
CIK:        0001490978
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0001490978-26-000036
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Schrödinger Q1 ACV $28.4M (+12%), drug disc. rev surges to $22.9M, net loss $60M, FY guide maintained
--------------------------------------------------------------------------------

- ACV $28.4M (+12% YoY); software revenue $35.6M (-21%) reflecting hosted transition.
- Drug discovery revenue surged to $22.9M from $10.2M on deferred revenue recognition and program discontinuation.
- Net loss $60.0M vs $59.8M; cash and securities $406M.
- Maintained FY2026 guidance: ACV $218-228M (10-15% growth), drug discovery revenue $55-65M.
- Planned summer launch of Bunsen agentic AI co-scientist; Lilly's $2.3B Ajax acquisition validates platform.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1490978/000149097826000036/0001490978-26-000036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1490978/000149097826000036/sdgr-20260505.htm
  HTML page:      https://secwatch.observer/filing/0001490978-26-000036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer